Yen plans to use a well-tolerated bio-agent to fundamentally improve the hospitability to T cells in brain tumors to enable effective immunotherapy
July 2021 – Yen’s DoD grant on brain tumor immunology just started
May 17, 2022 by zrb8mf@virginia.edu